Objective: Estrogen deficiency after menopause results in rapid bone loss, predisposing women to osteoporotic fractures. Genistein, a phytoestrogen present in high concentrations in soy, is an ingredient in dietary supplements aggressively marketed for bone health. However, in a recent long-duration clinical trial in postmenopausal women, the efficacy of soy extracts in reducing bone loss was disappointing. To better understand the failure of soy extracts to consistently induce a robust skeletal response in women, we investigated the long-term (5 mo) efficacy of genistein, administered as a daily oral supplement, (1) in preventing cancellous bone loss in skeletally mature virgin Long-Evans rats ovariectomized at 7 months of age and (2) in improving cancellous bone mass and architecture in aged retired-breeder rats ovariectomized at 16 or 22 months of age.
G enistein, an isoflavone present in high concentrations in soy, is classified as a phytoestrogen because of its ability to bind to and activate estrogen receptors (ERs). In legume, genistein functions as a chemoattractant for N 2 -fixing Rhizobium bacteria and as an endocrine disrupter to reduce predation. As a chemoattractant, genistein attracts Bradyrhizobium japonicum to plants by activating the bacterial nodD gene, which in turn promotes the expression of other nod genes. 1 The transcriptional products of these genes (nod factors) are bacteria-to-plant signaling molecules that are required for bacterial infection and plant root nodule organogenesis, as well as subsequent rhizobiaYlegume symbiosis and N 2 fixation. 2 The mechanism by which genistein induces nodD genes in bacteria has many similarities to the generegulatory pathway in animals involving nuclear receptorY ligand interactions. Because ligand binding regions of nodD in bacteria and ER in animals exhibit significant homology, it is probable that they originated from a common ancestor protein. 3 Genistein, besides binding to ERs in animals, has the capacity to interact with other nuclear receptors (including peroxisome proliferator-activated receptors in vertebrates) and with the ecdysone receptor in arthropods. 4 At high concentrations, genistein inhibits tyrosine kinase activity induced by the binding of natural ligands to epidermal growth factor receptor, platelet-derived growth factor receptor, insulin receptor, and kit receptor. 5 These findings suggest that genistein has the potential to influence numerous hormone-mediated pathways.
Hormonal regulation of physiological processes involves tight feedback control. The unregulated introduction of an exogenous ligand that can bind to a hormone receptor may disrupt physiological signaling through that receptor. By acting as an endocrine disrupter, genistein has been shown to impair reproduction in mice and molting in arthropods. 6<8 The ability to reduce predation by disrupting critical functions in vertebrate and arthropod herbivores would be of value to the evolutionary success of the legume.
Nonphysiological activation of ERs in select tissues may also confer context-specific benefits to vertebrates. For example, despite being a normal physiological process in humans, menopause results in greatly decreased serum estrogen levels and, as a consequence, rapid bone loss. 9 Hormone replacement is an effective pharmacological intervention to prevent bone loss. Phytoestrogens such as genistein, by virtue of their ability to bind to and activate ERs in bone cells, have the potential to exert a similar beneficial effect. 10 However, whether this occurs with the levels of dietary and supplemental intake of genistein is controversial. In the present study, we modeled the effects of oral genistein administered as a once-daily dietary supplement on bone density, mass, and architecture. Specifically, we determined the effect of longterm oral genistein on cancellous bone in the proximal tibial metaphysis and on cortical bone in the tibial diaphysis in skeletally mature ovariectomized 7-month-old virgin rats and aged ovariectomized 16-and 22-month-old retired-breeder rats. The mature ovariectomized rat has accurately predicted the effects of estrogen agonists, partial agonists, and antagonists on cancellous bone architecture and turnover in the human skeleton and is recommended by the Food and Drug Administration as a preclinical model for evaluating the safety and efficacy of drug interventions in preventing or treating postmenopausal osteoporosis. 11 
METHODS
The female Long-Evans rats used in this study to investigate the effects of genistein on bone metabolism comprised a subset of animals from a study evaluating the effect of oral genistein on cognitive function. 12 Long-Evans rats, although frequently used in cognitive research, are less commonly used in skeletal research. Therefore, validation studies were conducted to determine the effects of age, ovariectomy (ovx), and reproduction on cancellous and cortical bone in this strain of rat. In all our studies, the animals were housed in temperatureand humidity-controlled rooms on a 12-hour light-dark cycle, and all procedures were approved by the Institutional Animal Care and Use Committee. In all studies, the animals were randomly assigned to their respective treatment groups.
Experimental design Effect of age and ovx on bone in virgin Long-Evans rats
Seventy-two female virgin Long-Evans rats were used in validation experiments. The rats were randomized by weight to their respective groups. Untreated rats (8-12 rats/group) were killed at 2, 7, or 24 months of age. Additional rats (5-9 rats/group) underwent ovx or sham surgical operation at 2 months of age and were killed 1 or 2 months later at 3 or 4 months of age, respectively, or underwent ovx or sham surgical operation at 4 months of age and were killed 8 months later at 12 months of age.
Effect of reproduction on bone in Long-Evans rats
Compared with age-matched virgin rats, female retiredbreeder rats can be osteopenic as a consequence of multiple pregnancies and lactations. 11 To determine bone status before ovx in retired-breeder Long-Evans rats, we compared 6-month-old virgin rats, 12-month-old virgin rats, 12-monthold breeder rats retired from breeding at 8 months of age, and 12-month-old virgin rats ovariectomized at 7 months of age (n = 7-10 rats/group; total n = 35).
Effect of oral genistein on bone in virgin and retired-breeder Long-Evans rats
Eighty-nine female Long-Evans rats were used to investigate the effects of oral genistein on bone mass and architecture. The experimental protocol is described in detail elsewhere. 12 In brief ( Fig. 1 ), the effects of oral genistein on 7-month-old ovariectomized virgin rats (n = 7-10 rats/group), 16-month-old ovariectomized retired-breeder rats (n = 8-10 rats/group), and FIG. 1. Experimental protocol: 3-month-old virgin rats, 12-month-old retired-breeder rats, and 14-month-old retired-breeder rats were purchased and housed for 4 or 8 months before ovariectomy (ovx) at 7, 16, or 22 months of age, respectively. The rats within each age group were randomly assigned to one of three groups by using the same allocation probability for all groupsV(1) vehicle control, (2) genistein 485 Kg/day, or (3) genistein 970 Kg/dayVand treated daily for 5 months. After necropsy, the tibiae were evaluated for bone mass and architecture. 22-month-old ovariectomized retired-breeder rats (n = 11-12 rats/group) were evaluated. The rats were purchased and housed for 4 months (7-mo-old virgin rats and 16-mo-old retired-breeder rats) or 8 months (22-mo-old retired-breeder rats) before ovx. During this time, the animals were fed standard rat chow. On the day of ovx, the diet was switched into AIN-93G soy-free diet (Harlan-Teklad, Madison, WI) to avoid uncontrolled exposure to dietary phytoestrogens via feed. Treatment was administered using 97 mg of fruitflavored sucrose tablets (TestDiet, Richmond, IN; 1811494), which contained either 0.5% genistein or sucrose only. For treatment administration, the rats within each age group (7, 16, or 22 mo of age at the start of treatment) were assigned randomly by using the same probability of allocation into one of three groupsV(1) vehicle control (two sucrose tablets), (2) genistein 485 Kg/day (one sucrose tablet and one genistein tablet delivering approximately genistein 1.6 mg/kg/day), or (3) genistein 970 Kg/day (two genistein tablets delivering genistein at approximately 3.2 mg/kg/day)Vand treated daily for 5 months. We are aware that randomization is never an infallible mechanism for achieving balanced groups. However, animals within each age group shared similar life courses (eg, environment and diet). This alone diminishes concern for the prospect that unbalanced groups (with respect to measured and unmeasured covariates) were present in our study populations, and randomization adds to our confidence on having a high probability of balanced groups. For dosing, each rat was removed from its cage and given its dose individually. The tablets were consumed within a few seconds of presentation. For all studies, animals were killed using CO 2 , and tibiae were excised and preserved in 70% ethanol solution for analysis.
Dual-energy x-ray absorptiometry
Tibial bone mineral content (BMC; mg) and area (cm 2 ) were measured using dual-energy x-ray absorptiometry (DXA; Piximus; Lunar Corp., Madison, WI). Bone mineral density (BMD) was calculated as BMC per area (mg/cm 2 ). One individual performed all DXA analyses. The coefficient of variation for repeated scans (n = 5) of a single tibia is 1.9%, 1.1%, and 2.6% for area, BMC, and BMD, respectively.
Bone histomorphometry
For histomorphometric evaluation of cancellous bone in validation studies, proximal tibiae were dehydrated in a graded series of ethanol and xylene and embedded undecalcified in modified methyl methacrylate. Longitudinal sections (5 Km thick) were cut with a vertical bed microtome (Leica 2065) and affixed to slides. One section per animal was stained with toluidine blue. Bone volume/tissue volume (BV/TV; volume of tissue occupied by cancellous bone, %) was measured within the proximal tibial metaphysis, as described. 13 The region of interest (2.9 mm 2 ) included secondary spongiosa only.
For histomorphometric evaluation of cortical bone, crosssections (150 Km thick) were cut proximal to the tibiofibular junction using a low-speed IsoMet saw (Buehler, Lake Bluff, IL). Two sections per animal were ground to an approximate thickness of 20 Km and mounted unstained for microscopic assessment of cortical bone. Endpoints evaluated included cross-sectional area (area of cortical bone and bone marrow, mm 2 ), marrow area (mm 2 ), and cortical area (calculated as the difference between cross-sectional area and marrow area, mm 2 ).
All cancellous and cortical histomorphometric measurements were performed using the OsteoMeasure Analysis System (OsteoMetrics, Atlanta GA) and are reported using standard nomenclature. 14 One individual performed all histomorphometric analyses. The coefficient of variation for repeated measurements (n = 5) in a single tibia is 1.0% for BV/TV.
Micro-CT
Micro-CT (KCT) was used in the genistein dose response study for a nondestructive three-dimensional evaluation of bone architecture. Tibiae were scanned at a voxel size of 16 Â 16 Â 16 Km using a Scanco KCT40 scanner (Scanco Medical AG, Bassersdorf, Switzerland). The threshold for analysis was determined empirically and set at 245 (range, 0-1,000) for both cancellous bone and cortical bone. One hundred fifty slices (2.4 mm) in the proximal tibial metaphysis were evaluated. The volume of interest included secondary spongiosa only. Direct cancellous bone measurements included cancellous BV/TV (volume of tissue occupied by cancellous bone, %), connectivity density (number of redundant connections per unit volume, mm j3 ), trabecular number (number of trabecular intercepts, mm j1 ), trabecular thickness (mean thickness of individual trabeculae, Km), and trabecular separation (mean distance between trabeculae, Km). 15 Twenty slices (0.32 mm) in the tibial shaft 1.6 mm proximal to the tibiofibular junction were evaluated. Direct cortical measurements included cross-sectional area (area of cortical bone and bone marrow, mm 2 ), cortical area (mm 2 ), marrow area (mm 2 ), and cortical thickness (Km). One individual performed all KCT analyses. The coefficient of variation for repeated measurements (n = 5) in a single tibia is 1.1% for BV/TV and 0.6%, 0.9%, and 1.1% for cross-sectional area, cortical area, and marrow area, respectively.
Statistical analysis
The response variables BV/TV, cross-sectional area, marrow area, and cortical area were modeled using separate one-way analysis of variance (ANOVA). Comparisons were performed using F test and Tukey's honest significant difference method, which maintained the joint level of CIs at 95%. Linear model assumptions were assessed using normal quantile plots of residuals, plots of residuals versus fitted values, Levene's test for homogeneity of variance, and the Anderson-Darling test of normality. In the genistein studies, one-way ANOVA was used to evaluate differences among the treatment groups. If ANOVA distributional assumptions were not met, Kruskal-Wallis test was applied. Statistical analysis was performed using SPSS version 19.0 (SPSS Inc., Chicago, IL) and R version 2.12. 16 Differences were considered significant at P G 0.05. All data are expressed as mean (SE).
RESULTS

Effect of age and ovx on bone in virgin Long-Evans rats
The effect of age and ovx on BV/TV in the proximal tibial metaphysis of virgin Long-Evans rats is shown in Figure 2 . BV/TV increased between 2 and 3 months of age by an absolute value of 13.6% (95% CI, 6.3-20.8; P G 0.0001), remained stable between 3 and 12 months of age (F test, P = 0.62), and declined dramatically between 12 and 24 months of age by 19.7% (95% CI, 10.5-29.0; P G 0.0001). Compared with age-matched sham controls, rats ovariectomized at 2 months of age were severely osteopenic 1 and 2 months later when they were 3 and 4 months of age, respectively, with an age-adjusted estimated decrease in absolute BV/TV of 14.9% (95% CI, 11.9-17.9; P G 0.0001). However, BV/TV at these time points was similar to that in 2-month-old ovaryintact animals (F test, P = 0.44), indicating that ovx prevented the normal increase in BV/TV in growing rats. In contrast, rats ovariectomized at 4 months of age and killed 8 months later (12 mo of age) were osteopenic compared with baseline (4-mo-old ovary-intact) rats with a decreased BV/TV of 20.7% (95% CI, 11.8-29.7; P = 0.0002) and 12-monthold rats with a decreased BV/TV of 19.3% (95% CI, 9.8-28.8; P = 0.0005), indicating that ovx resulted in cancellous bone loss.
FIG. 2.
Effect of age (broken line) and ovariectomy (dotted line) on cancellous bone volume/tissue volume in the proximal tibial metaphysis, as determined by histomorphometry. Groups (n = 8-12 rats/group) of untreated rats were killed at 2, 7, or 24 months of age. Additional rats (n = 5-9 rats/group) underwent ovariectomy or sham surgical operation at 2 months of age and were killed at 3 or 4 months of age, or underwent ovariectomy or sham surgical operation at 4 months of age and were killed at 12 months of age. The lines approximate the best fit of the relevant data points. The lines between groups are meant to draw the eye to the different groups and to indicate some of the groups that were compared statistically. They are not meant to be used for statistical inference about the functional form between age and the response variables at unmeasured ages. Values are presented as mean (SE). a Different from aged-matched intact control, P G 0.05. b Different from baseline control, P G 0.05.
FIG. 3. Effect of age (broken line) and ovariectomy (dotted line) on cortical area (A)
, cross-sectional area (B), and marrow area (C) in the distal tibial diaphysis proximal to the tibiofibular junction, as determined by histomorphometry. Groups (n = 8-12 rats/group) of untreated rats were killed at 2, 7, or 24 months of age. Additional rats (n = 5-9 rats/group) underwent ovariectomy or sham surgical operation at 2 months of age and were killed at 3 or 4 months of age, or underwent ovariectomy or sham surgical operation at 4 months of age and were killed at 12 months of age. As in Fig. 1 , the lines approximate the best fit of the relevant data points. The lines are not meant to be used for statistical inference about the functional form between age and the response variables at unmeasured ages. Values are presented as mean (SE). a Different from aged-matched intact control, P G 0.05. b Different from baseline control, P G 0.05.
The effect of age and ovx on cortical bone in tibial diaphysis is shown in Figure 3 Cortical bone area increased by 1.3 mm 2 (95% CI, 0.9-1.8; P G 0.0001) between 2 and 7 months of age (Fig. 3A) . The growth-related increase in cortical bone area was caused by an increased cross-sectional area of 1.2 mm 2 (95% CI, 0.7-1.8; P G 0.0001; Fig. 3B ), with no change in marrow area (P = 0.82; Fig. 3C ). There was an increase in marrow area of 0.50 mm 2 (95% CI, 0.16-0.84;
FIG. 4. Effects of reproductive status on bone volume/tissue volume in the proximal tibial metaphysis, as determined by micro-CT. Representative micro-CT images for 6-month-old virgin rat (A), 12-month-old retired-breeder rat (B), and 12-month-old virgin rat ovariectomized at 7 months of age (C; n = 7-10 rats/group). Twelve-month-old retired-breeder rats were osteopenic compared with 6-month-old virgin rats, did not differ from 12-monthold ovary-intact virgin rats, and had higher BV/TV than 12-month-old virgin rats ovariectomized at 7 months of age (D). Values are presented as mean (SE). a Different from 6-month-old virgin rat, P G 0.05. b Different from 12-month-old virgin rat, P G 0.05. c Different from 12-month-old retired-breeder rat, P G 0.05. (12) 0.181 Data are presented as mean (SE). The rats were ovariectomized at 7 months of age and treated with one of two doses of genistein for 5 months (until 12 mo of age). BMC, bone mineral content; BMD, bone mineral density. P = 0.001) between 12 and 24 months of age, but this had no effect on cortical area. The marrow area in rats ovariectomized at 4 months of age and killed at 12 months of age was larger than the marrow area in sham-operated rats killed at 4 or 12 months of age by an estimated 0.3 mm 2 (95% CI, 0.03-0.6; P = 0.03) and 0.3 mm 2 (95% CI, 0.04-0.6; P = 0.03), respectively. Otherwise, no differences in cortical endpoints were detected with ovx.
Effect of reproduction on bone in Long-Evans rats
BV/TV in the proximal tibial metaphysis of 12-month-old breeder rats retired at 8 months of age was lower than BV/TV in 6-month-old virgin rats (Fig. 4 ). However, it was higher than BV/TV in 12-month-old virgin rats ovariectomized at 7 months of age.
Effect of oral genistein on bone in virgin and retired-breeder Long-Evans rats
Serum genistein was sampled from a subset of animals in each treatment and age group, and results are reported in detail elsewhere. 12 In brief, age had no independent effect on serum genistein levels, and values from the three different age groups per treatment were combined (n = 25 per treatment). Serum genistein measured 0.18 (0.10) KM in the control group, 0.76 (0.15) KM in the genistein 485 Kg/day dose group, and 1.48 (0.31) KM in the genistein 970 Kg/day dose group.
Seven-month-old ovariectomized virgin rats treated for 5 months
Significant differences in tibial BMC, bone area, or BMD were not detected among the three treatment groups ( Table 1) . All rats exhibited severe cancellous osteopenia, as indicated by the low BV/TV. However, significant differences in any cancellous endpoints measured (BV/TV, connectivity density, trabecular number, trabecular thickness, or trabecular spacing) were not detected among the three treatment groups. Similarly, significant differences in any cortical endpoints evaluated (cross-sectional area, cortical area, marrow area, or cortical thickness) were not detected among the three treatment groups.
Sixteen-month-old ovariectomized retired-breeder rats treated for 5 months Significant differences in tibial BMC, bone area, or BMD were not detected among the treatment groups ( Table 2 ). All rats exhibited severe cancellous osteopenia, as indicated by their low BV/TV. However, significant differences in any cancellous endpoint measured (BV/TV, connectivity density, trabecular number, trabecular thickness, or trabecular spacing) were not detected among the treatment groups. Similarly, significant differences in any cortical endpoint measured (crosssectional area, cortical area, marrow area, or cortical thickness) were not detected among the treatment groups.
Twenty-two-month-old ovariectomized retired-breeder rats treated for 5 months Significant differences in BMC, bone area, or BMD were not detected among the three treatment groups (Table 3) . Likewise, significant differences in any cancellous or cortical endpoints measured were not detected among the three treatment groups.
DISCUSSION
The goal of this study was to determine the effect of oral genistein on bone in a well-validated rat model for postmenopausal osteopenia. The effect of long-duration (administered daily for 5 mo) dietary genistein on cancellous and cortical bone mass and architecture in skeletally mature virgin Long-Evans rats ovariectomized at 7 months of age and in aging retired-breeder Long-Evans rats ovariectomized at 16 or 22 months of age was evaluated. Dietary genistein increased serum levels of the isoflavone to micromolar concentrationsV values achievable with a high-soy diet in women. 17, 18 However, the treatment had no effect on bone mass, density, or architecture either in skeletally mature ovariectomized virgin rats (a model for rapid bone loss after attainment of peak bone mass) or in aged ovariectomized retired-breeder rats (a model in which ovx exaggerates the bone loss associated with aging).
Long-Evans rats are frequently used in cognitive research, whereas Sprague-Dawley and Fisher rats are more commonly used as preclinical models in osteoporosis research. The similarity of the patterns of bone gain, maintenance, and agerelated and ovx-induced bone loss between Long-Evans rats (current study) and Sprague-Dawley and Fisher rats 19<21 supports the use of Long-Evans rats in cross-disciplinary research. Time-course changes support our choice of 7-monthold Long-Evans rats to investigate the efficacy of long-duration genistein treatment in preventing ovx-induced cancellous and endocortical bone loss. Based on our findings, cancellous and cortical bone mass remain stable between 7 and 12 months of age. As a consequence, age-related bone changes during the age range studied would not confound the interpretation of our results. In younger rats, ovx-induced osteopenia was largely caused by the prevention of the net accrual of cancellous bone, whereas 2-year-old animals exhibited pronounced age-related cancellous and endocortical bone loss. The mechanism for the age-related bone loss between 12 and 24 months of age is uncertain but may be related to the transition from regular estrus cycles into continuous anestrous cycles, a condition similar to menopause in women. 22 Pregnancy and lactation are reported to result in reversible cancellous osteopenia in Sprague-Dawley rats, 23, 24 a finding confirmed in the present study for Long-Evans rats. Specifically, BV/TV was lower in 12-month-old retired-breeder rats than in 6-month-old virgin rats. However, BV/TV in retiredbreeder rats killed at 21 and 27 months of age was even lower than BV/TV in 12-month-old retired-breeder rats, indicating further bone loss. Although the skeleton of aged ovariectomized rats becomes severely osteopenic, it remains responsive to bone-anabolic agents. 25 As a consequence, the putative bone-anabolic effect of genistein would be expected to result in increased bone mass compared with age-matched controls, which was not observed in the current study.
The effects of dietary soy, soy isoflavone extracts, and purified genistein on bone marrow stromal cells, osteoblastlike cells, and cultured osteoclasts have been evaluated in vitro and in vivo in animal models and humans. Antiresorptive and bone-anabolic effects of genistein have been reported. 26<29 Excellent in vitro evidence indicates that genistein is a weak ER ligand that has higher affinity for ER-A than for ER->. 30 However, genistein had only a slight preference for transactivation of gene expression through ER-A over ER-> 31 and thus may show minimal discrimination between the two receptor subtypes. Genistein significantly increased uterine wet weight in wild-type mice but not in ER-> knockout mice, providing direct evidence that genistein can act through ER->. 32 This may be important to the rodent skeleton because ER-> messenger RNA is present at higher levels in skeletal tissue than ER-A, and ER-A signaling may lead to bone loss by antagonizing ER-> signaling. 33 The precise actions of genistein on estrogen target tissues in vivo seem to be highly context-dependent: genistein can act as an estrogen agonist, can act as an antagonist, or can have no effect. 34<38 Clinical studies reporting the positive effects of soy and isoflavones on BMD in aging humans suggest that the isoflavones, particularly genistein and its metabolites, may mimic the bone-sparing actions of estrogen. However, relatively small numbers of participants were studied for relatively short intervals, and other similarly powered studies reported either minimal or no effect of treatment on the prevention of age-related bone loss. 39<41 A meta-analysis concluded that the results of these studies do not support an important effect of isoflavones on bone health. 42 Moreover, a more recent, long-duration, randomized, placebo-controlled, double-blind clinical trial reported no beneficial effects of soy isoflavones on bone health in postmenopausal women. In this clinical trial, no difference in BMD was detected between women receiving soy isoflavone tablets (200 mg/d) and women receiving placebo after 2 years of treatment. 43, 44 Thus, despite overwhelming evidence supporting the efficacy of hormone therapy in preventing osteoporotic fractures, neither reduction in bone loss nor reduction in fracture rate with ingestion of soy isoflavones has been convincingly demonstrated in postmenopausal women. Indeed, the latter would be extremely difficult to accomplish because of the large numbers of women required and the cost associated with performing a fracture study.
Animal studies have played a critical role in the preclinical evaluation of pharmaceuticals developed for the treatment of osteoporosis. 11 However, there has been no consensus regarding the efficacy of genistein in preventing bone loss in animal models. 45<50 Depending on the experimental design, model system used, mode of delivery, dose of genistein, and skeletal endpoints measured, genistein has been reported to have a wide range of effects on the skeleton and reproductive tissues. Most studies that investigated genistein's actions in animals were not designed to model the actions of either a once-daily supplement or an isoflavone-rich diet on postmenopausal bone loss. Many animal studies that reported a positive skeletal effect of genistein used high doses of the compound, administered the compound by injection (bypassing the low intestinal absorption efficiency of the phytoestrogen), used rapidly growing ovariectomized animals (which do not mimic postmenopausal bone loss), focused on skeletal endpoints such as BMD (which do not detect cancellous bone loss), and/or used mice (a species that does not respond to exogenous estrogens similarly to women). Thus, there is an important need to model the effects of soy, soy extracts, and purified isoflavones using well-validated preclinical animal models.
In the present study, genistein was administered orally as a once-daily dietary supplement to determine its effects on postmenopausal bone mass and architecture. Oral delivery is important because the efficacy and precise actions of an ER ligand depend on bioavailability, concentration, affinity for the receptor, and ability of the ligand-receptor complex to attract transcriptional coactivators and coinhibitors. Therefore, the delivery method of weak estrogens can drastically influence their actions on target tissues. For example, 16>hydroxyestrone, an important but weak endogenous estrogen in postmenopausal women, acts as a complete estrogen agonist of bone and reproductive tissues when administered once daily by subcutaneous injection. In contrast, infusion of 16>hydroxyestrone to model a continuous endogenous production of the metabolite results in preferential actions of the estrogen on bone over reproductive tissues. 51, 52 The differential tissue effects of estrogen ligands are hypothesized to result from the tissue-specific metabolism of the ligand. The significance of the tissue-level metabolism of steroid receptor ligands is beautifully illustrated by tibolone, a prodrug that, depending on tissue, can be metabolized into products that bind to estrogen, androgen, or progesterone receptors. 53, 54 Thus, the nonphysiological methods of administering isoflavones commonly used in phytoestrogen research may not accurately model the effects of dietary consumption on estrogen target tissues. Therefore, in the present study, we used the oral route of administration to deliver genistein at levels that could be achieved in the diet.
Prior studies often used densitometry as the primary method for evaluating skeletal response to phytoestrogens. Furthermore, BMD was often the only densitometry endpoint reported. Unfortunately, densitometry lacks sufficient sensitivity to dissociate changes in the highly responsive cancellous bone compartment from changes in the much larger but less responsive cortical bone compartment. As clearly illustrated in the present study, bone loss in ovariectomized rats is largely confined to the cancellous compartment, and cancellous bone loss is especially important to the etiology of vertebral and hip fractures. Gonadal hormones, by acting differentially on periosteal and endocortical bone envelopes, alter bone size and BMC 55 Vthe two variables used to calculate BMD. In growing animals, estrogens slow longitudinal bone growth by inhibiting chondrocyte proliferation and hypertrophy but increase cancellous bone volume fraction by suppressing resorption of primary spongiosa. 56 As a consequence, the physical significance of BMD is not easily interpretable in the absence of supporting documentation (BMC and bone size). In the present study, DXA was used to evaluate bone mass (BMC) and areal density (BMD). However, we also used high-resolution KCT to evaluate cortical and cancellous bone architecture.
The mouse is being used increasingly to investigate the actions of phytoestrogens (including genistein) on bone metabolism. The skeletal response of the mouse to estrogen is a sensitive bioassay for exogenous estrogens; however, as reviewed previously, 11 mice are a poor preclinical model for evaluating the differential actions of estrogenic compounds on bone and reproductive tissues. A case in point is that the mouse failed to predict the tissue-selective actions of the breast cancer drug tamoxifen and its metabolites on bone and reproductive tissues or the inhibitory effects of estrogen on bone turnover universally observed in humans. 57, 58 Estrogens administered to mice do not replicate the skeletal actions of the hormone administered to humans nor the physiological actions of endogenous estrogen production in mice. 59 In mice, even weak exogenous estrogens are capable of inducing severe bone marrow failure and osteosclerosis. 60 Thus, the many studies that demonstrated increased BMD in mice in response to phytoestrogens may in fact have detected an exclusively mouse-specific skeletal pathology. 61, 62 We have reviewed the strengths and limitations of the ovariectomized rat as a preclinical model for postmenopausal bone loss. 11, 63 Briefly, the rat has been valuable in accurately predicting the beneficial effects of the major classes of pharmaceuticals (eg, estrogens, selective ER modulators, bisphosphonates, and parathyroid hormone) approved for the prevention and/or treatment of osteoporosis. The rat has been particularly useful for modeling cancellous and endocortical bone loss. Because of the absence of Haversian remodeling in small rodents, the rat is less useful for evaluating the effects of these agents on intracortical bone remodeling.
The present study focused on the efficacy of purified genistein in preventing ovx-induced cancellous and endocortical bone loss in tibia. It is possible, however, that other components of soy influence the bioactivity of genistein. Although the tibia is representative of the skeletal response to ovx and hormone therapy in adult rats, 64, 65 it is also possible that genistein exhibits greater effects at other skeletal sites. The present study evaluated the efficacy of genistein in preventing bone loss after ovx; the study provides no insight into the possible effects of genistein on bone mass and architecture if administered to ovary-intact rats. Finally, the present study focused on blood levels of genistein that could be achieved via a once-daily supplement similar to levels obtainable via a soyrich diet. The studies do not address the possible skeletal effects of higher levels of genistein.
CONCLUSIONS
The results of the studies described here support neither a detrimental effect nor a protective effect of dietary genistein on bone mass, density, and architecture in well-validated preclinical models for postmenopausal bone loss. We cannot rule out the possibility that genistein levels exceeding reasonable dietary intake may impact the skeleton. Herbivores and omnivores may have developed resistance to the endocrinedisrupting effects of genistein, first by limiting its intestinal absorption and second by inducing its rapid excretion. 66 Although pharmacological administration of the isoflavone seems to be a strategy for bypassing these defenses, it is unclear whether this is a desirable approach considering the potential for serious detrimental adverse effects. 67<69
